How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Romosozumab for treating severe osteoporosis

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about romosozumab

    Marketing authorisation indication

    2.1 Romosozumab (EVENITY, UCB) is indicated for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

    Dosage in the marketing authorisation

    2.2 The dosage schedule is available in the summary of product characteristics.

    Price

    2.3 The price for romosozumab is £427.75 for 2 pre-filled pens administered subcutaneously as a single monthly dose (BNF online, October 2021). The company has a commercial arrangement. This will make romosozumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.